European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase 3 KEYNOTE-426 [...]
NHS saves more than £700 million on medicines bill
The NHS has announced that it has saved more than [...]
Right-sided kidney tumours have better outcomes
In a recent paper published in Cancer Medicine from researchers [...]
Hereditary kidney cancer – new syndromes
A recent review of the literature in European Urology summarises [...]
NHS Rapid Diagnostic Centres – vision and implementation specification
The NHS Cancer Programme has published the Vision and 2019/20 [...]
Phase Ib cabozantinib plus atezolizumab combination study now open to kidney cancer patients in the UK
Based on promising efficacy findings, the COSMIC-021 clinical trial has [...]
Comparing long-term outcomes for partial and radical nephrectomy
Using the National Cancer Database, 3009 patients with low stage [...]
Nivolumab demonstrates long term survival in advanced kidney cancer
A new study published in JAMA Oncology shows that treatment [...]
European Medicines Agency approves pembrolizumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Outcomes of metastatic kidney cancer patients treated with first-line immunotherapy and second-line VEGFR-TKI
The standard of care recommended for the treatment of patients [...]
